Trial Profile

A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 31 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ruxolitinib (Primary)
Indications Atopic dermatitis
Focus Registrational; Therapeutic Use
Acronyms TRuE-AD4
Sponsors Incyte Corporation

Most Recent Events

28 Oct 2025 Status changed from active, no longer recruiting to completed.
25 Oct 2025 Results presented in the Incyte Corporation media release.
25 Oct 2025 According to Incyte Corporation media release, company will present updated result data from this study during the Systemic and New Therapies for Atopic Dermatitis session on Sunday, October 26 at the 15th Georg Rajka International Symposium on Atopic Dermatitis (ISAD).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com